NEW YORK, Nov. 24, 2016 /PRNewswire/ -- The Global Tuberculosis Diagnostics and Treatments Market is poised to grow at a CAGR of around 4.2% from 2015 to 2025. Some of the prominent trends that the market is Technologies that may replace smear microscopy continue to expand, Major investments in basic research related to Mycobaterium tuberculosis diagnosis, Demand for Xpert MTB/RI in the tuberculosis diagnostics landscape and Potential Market in Most of the Emerging Nations of the World.
Based on Therapeutics the market is categorized into Tuberculosis Drugs (First Line) and Tuberculosis Drugs (Second Line). The Tuberculosis Drugs (First Line) segment is Isoniazid (INH), Rifampin (RIF), Ethambutol (EMB) and Pyrazinamide (PZA). Tuberculosis Drugs (Second Line) segment is further represented as Aminoglycosides, Fluoroquinolones, Polypeptides, Thioamides, Cycloserine, p-Aminosalicylic Acid and Other Drugs.
Based on Diagnosis the market is categorized into Skin Testing and Laboratory Testing. TheLaboratory Testing segment is further categorized into Adenosine Deaminas, Nucleic Acid Amplification Tests (NAAT), Interferon Gamma Release Assay, Antibody/Antigen Detection, Culture-Based Systems, Non-Culture Methods, Chest X-rays and computer-aided diagnosis, Biomarkers for active or latent TB, Serodiagnostic assays, Microscopy and associated tools, Cytokine detection assay, Smear Microscopy and Drug Susceptibility Testing (DST).
This industry report analyzes the global markets for Tuberculosis Diagnostics across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc. The market data is gathered from extensive primary interviews and secondary research. The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.
The Tuberculosis Diagnostics Market report provides data tables, includes charts and graphs for visual analysis.
- Rest of Europe
- New Zealand
- Rest of Asia
- Saudi Arabia
- Rest of Middle East
- Rest of Latin America
Rest of the World
- The report provides a detailed analysis on current and future market trends to identify the investment opportunities
- Market forecasts till 2025, using estimated market values as the base numbers
- Key market trends across the business segments, Regions and Countries
- Key developments and strategies observed in the market
- Market Dynamics such as Drivers, Restraints, Opportunities and other trends
- In-depth company profiles of key players and upcoming prominent players
- Growth prospects among the emerging nations through 2025
- Market opportunities and recommendations for new investments
Read the full report: http://www.reportlinker.com/p04366672-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-tuberculosis-diagnostics-and-treatment-market-analysis--trends--therapeutics-rifampin-rif-pyrazinamide-pza-thioamides-and-fluoroquinolones-diagnosis---forecast-to-2025-300368543.html